Stocks and InvestingStocks and Investing
Wed, January 4, 2023
Tue, January 3, 2023
Fri, December 30, 2022
Thu, December 29, 2022
Wed, December 28, 2022
Tue, December 27, 2022
Fri, December 23, 2022
Thu, December 22, 2022
Wed, December 21, 2022

Uy Ear Maintained (ACAD) at Hold with Decreased Target to $15 on, Dec 21st, 2022


Published on 2024-10-28 00:40:50 - WOPRAI, Uy Ear
  Print publication without navigation


Uy Ear of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $17 to $15 on, Dec 21st, 2022.

Uy has made no other calls on ACAD in the last 4 months.



There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
  • Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Uy


  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022